Published on Jun 22, 2012
Rottenstein Law Group, LLP
321 W 44th St # 804
New York, NY 10036
Not long ago, the public was given its first vaginal mesh FDA warning... that is, the U.S. Food and Drug Administration began to issue cautions about the complications and side effects associated with vaginal mesh products.
In 2008, the FDA released its first public health communication cautioning doctors about the risks associated with surgical mesh. This warning was issued in response to the receipt of over 1,000 adverse-event reports about surgical mesh products used to treat POP and SUI.
Between 2008 and 2010, the number of serious complaints to the FDA about complications related to the use of surgical mesh to treat POP increased five-fold.
Moreover, the agency's review of relevant scientific literature published from 1996 to 2011 showed that transvaginal POP repair with mesh does not improve symptomatic results or quality of life over traditional non-mesh repair.
Accordingly, the FDA issued another safety communication on July 13, 2011, this time announcing that "serious complications associated with surgical mesh for transvaginal repair of POP are not rare."
The most consistently reported complication to arise in connection with the use of surgical mesh to treat proplapse has been erosion: the mesh wears through the vaginal mucosa and exposes its rough and uncomfortable surface to the patient and her partner. Patients also report instances of mesh contraction (shrinkage).
Other side effects that transvaginal mesh patients reported include:
• Urinary problems
• Blood vessel, bladder, or bowel perforation
• Vaginal tightening
• Pain during sex
The Rottenstein Law Group knows that you've suffered. You shouldn't have to go through more trouble to be compensated. RLG will be with you at every step of the process of demanding satisfaction, which we'll make as efficient as possible.
You've taken enough. We'll take it from here. Call us today at 888-419-9511.